Curasight

Curasight's CEO Ulrich Krasilnikoff comments:

"During the fourth quarter we built on the momentum from earlier in the year to advance our strategy of parallel development of both our therapeutic uTREAT® and diagnosistic uTRACE® platforms. A key milestone was to select brain cancer as the initial clinical indication for uTREAT, enabling us to conduct a relatively small trial and establish proof of concept in humans within a shorter time frame. Additionally, we remained active in business development, engaging in discussions on potential industry collaborations. Despite ongoing macroeconomic challenges, we also continued to explore strategic fundraising opportunities to strengthen our financial foundation in the future. I look forward to updating you further on our activities in this area during 2025".

Q4 (2024-10-01 - 2024-12-31)

• Gross loss amounted to kDKK -10,210 (kDKK -5,493)
• Operating loss amounted to kDKK -11,721 (kDKK -7,354)
• Loss before tax amounted to kDKK -12,334 (kDKK -7,907)
• Loss for the period amounted to kDKK -12,334 (kDKK -6,413)
• Total assets amounted to kDKK 22,314 (kDKK 38,742)
• Equity ratio amounted to 28.4% (81.0%)
• Earnings per share amounted to DKK -0.58 (DKK -0.32)

Q1-Q4 (2024-01-01 - 2024-12-31)

• Gross loss amounted to kDKK -32,731 (kDKK -26,169)
• Operating loss amounted to kDKK -40,367 (kDKK -33,214)
• Loss before tax amounted to kDKK -42,336 (kDKK -33,220)
• Loss for the period amounted to kDKK -38,211 (kDKK -26,169)
• Total assets amounted to kDKK 22,314 (kDKK 38,742)
• Equity ratio amounted to 28.4% (81.0%)
• Earnings per share amounted to DKK -1.81 (DKK -1.32)

Numbers in parenthesis are the numbers from the same period in 2023.

Curasight intends to publish the Annual Report 2024 on March 26, 2025, in connection with the notice of the Annual General Meeting 2025.